CIK 0001590750
- Large accelerated filer
Viridian Therapeutics, Inc.DE
Sign in to watch- Ticker
- VRDN
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 471187261
- Phone
- +1 617-272-4600
- Business address
- 221 CRESCENT STREET, SUITE 103A, WALTHAM, MA, 02453
- Former names
- MIRAGEN THERAPEUTICS, INC., SIGNAL GENETICS, INC., SIGNAL GENETICS LLC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-03-03 | Beetham Thomas W. Chief Operating Officer | Shares withheld for taxes | −3,048 | $30.19 | $92K | 13,361 |
| 2026-03-03 | Beetham Thomas W. Chief Operating Officer | Exercise or conversion | +9,409 | 16,409 | ||
| 2026-03-03 | Beetham Thomas W. Chief Operating Officer | Shares withheld for taxes | −3,138 | $29.32 | $92K | 13,271 |
| 2026-03-03 | Beetham Thomas W. Chief Operating Officer | Exercise or conversion · Restricted Stock Units | −9,409 | 28,227 | ||
| 2026-03-02 | Beetham Thomas W. Chief Operating Officer | Grant or award · Stock Option (Right to Buy) | +176,550 | 176,550 | ||
| 2026-03-02 | Beetham Thomas W. Chief Operating Officer | Grant or award · Restricted Stock Units | +35,300 | 35,300 | ||
| 2025-03-03 | Beetham Thomas W. Chief Operating Officer | Grant or award · Stock Option (Right to Buy) | +225,814 | 225,814 | ||
| 2025-03-03 | Beetham Thomas W. Chief Operating Officer | Grant or award · Restricted Stock Units | +37,636 | 37,636 | ||
| 2024-09-27 | Beetham Thomas W. Chief Operating Officer | Purchase | +5,000 | $23.41 | $117K | 6,000 |
| 2023-10-30 | Beetham Thomas W. Chief Operating Officer | Grant or award · Stock Option (Right to Buy) | +474,400 | 474,400 |
Page 1 of 1 · 10 trades